{"id":"ivabradine-usual-care","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Visual disturbances (luminopsia)"},{"rate":null,"effect":"Phosphenes"},{"rate":null,"effect":"Atrial fibrillation"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivabradine works by blocking the hyperpolarization-activated cyclic nucleotide-gated channel (HCN) that mediates the funny current, which is responsible for diastolic depolarization in pacemaker cells. This selective heart rate reduction improves myocardial oxygen supply-demand balance in heart failure patients. The combination with usual care aims to provide additive symptomatic and potentially prognostic benefits in heart failure management.","oneSentence":"Ivabradine selectively inhibits the funny current (If) in the sinoatrial node to reduce heart rate without affecting blood pressure or contractility.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:42.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction (HFrEF) in combination with standard therapy"},{"name":"Symptomatic chronic heart failure"}]},"trialDetails":[{"nctId":"NCT06305780","phase":"PHASE2","title":"RECOVER-AUTONOMIC Platform Protocol","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Covid19, Long Covid-19","enrollment":381},{"nctId":"NCT06305806","phase":"PHASE2","title":"RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Covid19, Long Covid-19","enrollment":181},{"nctId":"NCT07135258","phase":"PHASE4","title":"Atrial Fibrillation: In Search for the Optimal Target for Rate Control","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-10-01","conditions":"Atrial Fibrillation (Permanent), Atrial Fibrillation (AF)","enrollment":200},{"nctId":"NCT05572957","phase":"NA","title":"LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10-14","conditions":"Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block","enrollment":50},{"nctId":"NCT04030546","phase":"PHASE3","title":"Ivabradine to Prevent Anthracycline-induced Cardiotoxicity","status":"UNKNOWN","sponsor":"Vilnius University","startDate":"2019-06-01","conditions":"Patients With Cancer","enrollment":128},{"nctId":"NCT02827500","phase":"PHASE4","title":"Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-07","conditions":"Heart Failure","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ivabradine + Usual Care","genericName":"Ivabradine + Usual Care","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivabradine selectively inhibits the funny current (If) in the sinoatrial node to reduce heart rate without affecting blood pressure or contractility. Used for Heart failure with reduced ejection fraction (HFrEF) in combination with standard therapy, Symptomatic chronic heart failure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}